GSK to Buy Sirtris

Drug Industry Daily
A A
GlaxoSmithKline (GSK) has offered to buy all outstanding shares of Sirtris Pharmaceuticals for $22.50 a share.

To View This Article:

Login

Subscribe To Drug Industry Daily